ReviewThe Lancet. Infectious diseases2019
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
Review in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.AIDS research and therapy · 2020Pooled it
- Impact of Dolutegravir-Based Antiretroviral Therapy on Viral Load Suppression and Uptake of DTG-Based Regimen Among Pediatric HIV Patients in Africa: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS CarePooled it
- Clinical and Epidemiological Profile of Dolutegravir Use and Antiretroviral Resistance in Honduras.Health education & behavior : the official publication of the Society for Public Health Education · 2026Article
- Non-integrase mechanisms for dolutegravir resistance.Retrovirology · 2026Review
- Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study.BMJ global health · 2026Observational
- HIV-1 genetic diversity and pretreatment drug resistance survey prior to dolutegravir introduction in Senegal.IJID regions · 2025Article
- HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Treatment of Advanced HIV in the Modern Era.Drugs · 2025Review
- Monitoring of virological response and acquired HIV-1 drug resistance among patients initiating antiretroviral therapy in the Centre Region of Cameroon.The Pan African medical journal · 2025Article
- Impact of V179D/E mutations on antiretroviral therapy outcomes in people living with HIV-1: a 3-year retrospective study.Frontiers in cellular and infection microbiology · 2025Article
- Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DFThe Lancet regional health. Western Pacific · 2024Article
- HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.Scientific reports · 2024Article
- The impact of the COVID-19 pandemic on people living with HIV: a cross-sectional study in Caracas, Venezuela.BMC infectious diseases · 2024Article
- The rollout of paediatric dolutegravir and virological outcomes among children living with HIV in Mozambique.Southern African journal of HIV medicine · 2024Article
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.The lancet. HIV · 2023Article
- Article
- Population prevalence of antiretroviral therapy sharing and its association with HIV viremia in rural Uganda: a cross-sectional population-based study.Journal of the International AIDS Society · 2023Article
- Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.Open forum infectious diseases · 2023Article
- Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To improve virological suppression and address the emerging threat of HIV drug resistance, many low-income and middle-income countries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioning to dolutegravir as part of a more affordable and standardised antiretroviral therapy (ART). Although this transition could decrease the effect of rising NNRTI resistance and yield improved ART outcomes, it also presents new challenges. First, current safety concerns for dolutegravir use in women of childbearing potential require alternative solutions. Second, pre-existing resistance to the co-administered nucleoside reverse transcriptase inhibitors might reduce effectiveness and durability of dolutegravir, particularly if there is scarce access to viral load tests to monitor treatment outcomes. Third, there is inadequate information on the genetic correlates of resistance to dolutegravir, particularly in patients infected with HIV-1 non-B subtypes. Finally, clinical management of patients with confirmed virological failure on a dolutegravir-based regimen can pose challenges because of uncertainty around whether dolutegravir resistance has actually developed and switching is needed, or whether only interventions to improve adherence without switching are sufficient. These considerations should be addressed to consolidate expected gains from widespread introduction of dolutegravir in low-income and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.